Kokuina E

Language: English
References: 10
Page: 90-91
PDF size: 118.72 Kb.

Text Extraction

Systemic lupus erythematosus (SLE) is an autoimmune disease of unknown etiology. The only means of reducing its morbidity and mortality remains early diagnosis followed by timely medical treatment. SLE affects all populations worldwide, although prevalence rates differ between population groups, with higher rates among women of reproductive age and for African, Asian, and Hispanic ethnicities.
The possibility of SLE diagnosis should be kept in mind during daily medical practice, not because of its high frequency, but because of the pronounced heterogenicity of its clinical presentation; of all autoimmune diseases, SLE probably has the greatest diversity in clinical manifestations. Biomarkers that can diagnose and differentiate SLE from other rheumatic autoimmune diseases are needed. However, in more than 50 years of research, no single biomarker has emerged capable of identifying SLE in diagnostic tests.

REFERENCES

1. Stojan G, Petri M. Epidemiology of systemic lupus erythematosus: an update. Curr Opin Rheumatol. 2018 Mar;30(2):144–50.

2. Aringer M, Costenbader K, Daikh D, Brinks R, Mosca M, Ramsey-Goldman R, et al. European league against rheumatism/American College of Rheumatology classifi cation criteria for systemic lupus erythematosus. Ann Rheum Dis. 2019 Sep;78(9):1151–9.

3. Arriens C, Wren JD, Munroe ME, Mohan C. Systemic lupus erythematosus biomarkers: the challenging quest. Rheumatology (Oxford). 2017 Apr 1;56(Suppl 1):i32–i45.

4. Schmajuk G, Hoyer BF, Aringer M, Johnson SR, Daikh DI, Dörner T, et al. Multicenter Delphi exercise to identify important key items for classifying systemic lupus erythematosus. Arthritis Care Res (Hoboken). 2018 Oct;70(10):1488–94.

5. Toubi E, Shoenfeld Y. Clinical and biological aspects of anti-P-ribosomal protein autoantibodies. Autoimmun Rev. 2007 Jan;6(3):119–25.

6. Choi MY, FitzPatrick RD, Buhler K, Mahler M, Fritzler MJ. A review and metaanalysis of anti-ribosomal P autoantibodies in systemic lupus erythematosus. Autoimmun Rev. 2020 Mar;19(3). Art 102463. DOI: https://doi.org/10.1016/j .autrev.2020.102463

7. Damoiseaux J, von Mühlen CA, García-de la Torre I, Carballo OG, de Melo CW, Francescantonio PL, et al. International consensus on ANA patterns (ICAP): the bumpy road towards a consensus on reporting ANA results. Auto Immun Highlights. 2016 Dec;7(1):1.

8. Li J, Shen Y, He J, Jia R, Wang X, Chen X, et al. Signifi cance of antibodies against the native ribosomal P protein complex and recombinant P0, P1, and P2 proteins in the diagnosis of Chinese patients with systemic lupus erythematosus. J Clin Lab Anal. 2013 Mar;27(2):87–95.

9. Kokuina E, Milian OlivaresY, Tamargo Barbeito TO, Chico Capote A, Estevez del Toro M, Andux Valdés JL. Inmunocomplejos circulantes en el lupus eritematoso sistémico. Rev Cuba Med. 2020 Jan–Mar;59(1):e1337. Spanish.

10. Kokuina E, Chico Capote A, Estevez del Toro M, Tamargo Barbeito T, Milian Olivares, Sanchez Bruzon Y. (2020), Anticuerpos anti-proteína P ribosomal: utilidad diagnóstica en el lupus eritematoso sistémico y asociación con nefritis lúpica, Original Research. [Unpublished study]. Spanish.